Kinelimod (Fingolimod)

• Kinelimod (fingolimod) belongs to the class of sphingosine‑1‑phosphate receptor modulators and is employed as a disease‑modifying therapy for multiple sclerosis. By preventing egress of lymphocytes from lymph nodes, it lowers circulating immune cells that can infiltrate the central nervous system. The medication is approved for adult patients with the relapsing‑remitting form of multiple sclerosis, where it has been shown in clinical trials to lower the annualized relapse rate, reduce new or enlarging MRI lesions, and slow the accumulation of disability over time.
• Relapsing‑remitting multiple sclerosis: reduces the frequency of clinical relapses, decreases new MRI lesions, and slows disability progression.

• Fingolimod is a selective modulator of sphingosine‑1‑phosphate (S1P) receptors, primarily S1P1, on lymphocytes. Binding induces internalization of the receptor, which traps lymphocytes within lymph nodes and prevents their circulation to peripheral blood. The resulting lymphopenia diminishes the autoimmune attack on myelin in the central nervous system, thereby reducing inflammatory demyelination in multiple sclerosis. This mechanism provides a disease‑modifying effect by limiting immune cell infiltration into the CNS.

Fingolimod may cause a range of adverse reactions, which are categorized by frequency and severity.

Common Side Effects

• Headache: mild to moderate headache reported.
• Diarrhea: loose stools or increased bowel movements.
• Upper respiratory tract infection: symptoms such as cough or sore throat.
• Elevated liver enzymes: mild transaminase increase detected in laboratory tests.

Serious or Rare Side Effects

• Severe infections: opportunistic infections including herpes zoster.
• Cardiac effects: bradyarrhythmia or atrioventricular block, especially after first dose.
• Macular edema: swelling of the central retina that may affect vision.

Before initiating Kinelimod, clinicians should evaluate several safety considerations to minimize risk.

• Baseline cardiac assessment: obtain ECG and monitor heart rate before first dose.
• Infection screening: assess for active infections and vaccinate appropriately prior to therapy.
• Liver function monitoring: check hepatic enzymes at baseline and periodically during treatment.
• Vaccination timing: avoid live vaccines while on therapy and schedule inactivated vaccines before starting.
• Pregnancy and lactation: contraindicated in pregnancy; advise effective contraception and discuss risks if breastfeeding.
• Store at ambient temperature: keep below 25 °C in original packaging, protect from moisture and direct sunlight.

Fingolimod can interact with other medicines, altering its efficacy or safety profile.

Major Interactions (Avoid)

• CYP4F2 inhibitors: may increase fingolimod plasma concentrations.
• Strong CYP3A4 inducers: can reduce fingolimod exposure, decreasing effectiveness.
• Vaccines: live attenuated vaccines may cause severe infection; avoid concurrent use.

Moderate Interactions (Monitor Closely)

• Anticholinergic agents: may exacerbate bladder dysfunction.
• Antihypertensives: potential additive effect on blood pressure lowering.
• Other immunosuppressants: increased risk of infections; monitor closely.